3,688
edits
Neuromuscular Blockade: Difference between revisions
no edit summary
No edit summary |
No edit summary |
||
| Line 12: | Line 12: | ||
[https://www.bjanaesthesia.org/article/S0007-0912(19)30835-9/fulltext Comparison of incidence of anaphylaxis between sugammadex and neostigmine: a retrospective multicentre observational study] | [https://www.bjanaesthesia.org/article/S0007-0912(19)30835-9/fulltext Comparison of incidence of anaphylaxis between sugammadex and neostigmine: a retrospective multicentre observational study] | ||
Faulk DJ, Austin TM, Thomas JJ, Strupp K, Macrae AW, Yaster M. A Survey of the Society for Pediatric Anesthesia on the Use, Monitoring, and Antagonism of Neuromuscular Blockade. Anesth Analg 2021;132:1518-26. | |||
Hristovska AM, Duch P, Allingstrup M, Afshari A. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev 2017;8:Cd012763. | |||
Hristovska AM, Duch P, Allingstrup M, Afshari A. The comparative efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. A Cochrane systematic review with meta-analysis and trial sequential analysis. Anaesthesia 2018;73:631-41. | |||
Saager L, Maiese EM, Bash LD, Meyer TA, Minkowitz H, Groudine S, Philip BK, Tanaka P, Gan TJ, Rodriguez-Blanco Y, Soto R, Heisel O. Incidence, risk factors, and consequences of residual neuromuscular block in the United States: The prospective, observational, multicenter RECITE-US study. J Clin Anesth 2019;55:33-41. | |||